Dolan ME - Search Results

1

Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.

El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC Jr, Frisina RD, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Gamazon ER, Cox NJ, Huddart R, Ardeshir-Rouhani-Fard S, Monahan P, Fossa SD, Einhorn LH, Travis LB, Dolan ME. El Charif O, et al. Among authors: dolan me. Clin Cancer Res. 2019 Jul 1;25(13):4104-4116. doi: 10.1158/1078-0432.CCR-18-3179. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952644 Free PMC article.

2

Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.

Wu MH, Lohrbach KE, Olopade OI, Kokkinakis DM, Friedman HS, Dolan ME. Wu MH, et al. Among authors: dolan me. Clin Cancer Res. 1999 Jan;5(1):209-13. Clin Cancer Res. 1999. PMID: 9918221

3

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.

Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE. Humerickhouse RA, et al. Among authors: dolan me. Clin Cancer Res. 1999 Feb;5(2):291-8. Clin Cancer Res. 1999. PMID: 10037177 Clinical Trial.

4

In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo.

Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. Chmura SJ, et al. Among authors: dolan me. Clin Cancer Res. 2000 Feb;6(2):737-42. Clin Cancer Res. 2000. PMID: 10690561

5

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.

Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Schilsky RL, et al. Among authors: dolan me. Clin Cancer Res. 2000 Aug;6(8):3025-31. Clin Cancer Res. 2000. PMID: 10955780 Clinical Trial.

6

Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.

Dolan ME, Posner M, Karrison T, Radosta J, Steinberg G, Bertucci D, Vujasin L, Ratain MJ. Dolan ME, et al. Clin Cancer Res. 2002 Aug;8(8):2519-23. Clin Cancer Res. 2002. PMID: 12171878 Clinical Trial.

7

Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.

Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, Badner JA. Dolan ME, et al. Cancer Res. 2004 Jun 15;64(12):4353-6. doi: 10.1158/0008-5472.CAN-04-0340. Cancer Res. 2004. PMID: 15205351

8

A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.

Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. Huang RS, et al. Among authors: dolan me. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63. doi: 10.1073/pnas.0703736104. Epub 2007 May 30. Proc Natl Acad Sci U S A. 2007. PMID: 17537913 Free PMC article.

9

Mapping genes that contribute to daunorubicin-induced cytotoxicity.

Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, Dolan ME. Duan S, et al. Among authors: dolan me. Cancer Res. 2007 Jun 1;67(11):5425-33. doi: 10.1158/0008-5472.CAN-06-4431. Cancer Res. 2007. PMID: 17545624 Free PMC article.

10

Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis.

Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME. Shukla SJ, et al. Among authors: dolan me. Pharmacogenet Genomics. 2008 Mar;18(3):253-62. doi: 10.1097/FPC.0b013e3282f5e605. Pharmacogenet Genomics. 2008. PMID: 18300947 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page